Background: Augmentation of the anterior vaginal wall, commonly referred to as G-spot amplification (GSA), has gained increasing interest as a minimally invasive procedure aimed at improving female sexual satisfaction. Injectable therapies such as cross-linked hyaluronic acid (HA) and platelet-rich plasma (PRP) have been proposed for this purpose; however, comparative clinical data evaluating sexual outcomes remain limited. Objective: To compare the impact of anterior vaginal wall augmentation using cross-linked HA versus PRP on female sexual function, assessed using the Female Sexual Function Index (FSFI). Methods: A prospective comparative pilot study was conducted including 16 sexually active women undergoing anterior vaginal wall augmentation. Patients were allocated into two groups: a HA group (n = 8) treated with cross-linked HA (Armonía®) and a PRP group (n = 8) treated with autologous PRP. Sexual function was evaluated using the FSFI questionnaire at baseline and at 3 months post-treatment. Changes in total FSFI scores and domain-specific outcomes were analyzed within and between groups. Results: Both treatment groups demonstrated statistically significant improvements in total FSFI scores compared with baseline. The HA group showed a mean improvement exceeding 68%, with particularly notable gains in desire, arousal, and orgasm domains. The PRP group also exhibited significant improvement, although to a slightly lesser extent. Between-group comparison revealed a statistically significant difference favoring HA treatment (p < 0.05). No major adverse events were reported. Conclusion: Anterior vaginal wall augmentation using both cross-linked HA and PRP appears to be a safe and effective minimally invasive approach to enhance female sexual satisfaction. HA demonstrated a greater short-term improvement in FSFI scores, although PRP also provided meaningful clinical benefits. Larger randomized controlled studies with longer follow-up are warranted.